RU2020117081A - Жидкие стабильные вакцины, содержащие вирус крупного рогатого скота - Google Patents
Жидкие стабильные вакцины, содержащие вирус крупного рогатого скота Download PDFInfo
- Publication number
- RU2020117081A RU2020117081A RU2020117081A RU2020117081A RU2020117081A RU 2020117081 A RU2020117081 A RU 2020117081A RU 2020117081 A RU2020117081 A RU 2020117081A RU 2020117081 A RU2020117081 A RU 2020117081A RU 2020117081 A RU2020117081 A RU 2020117081A
- Authority
- RU
- Russia
- Prior art keywords
- live attenuated
- liquid stable
- combination vaccine
- stable combination
- bvdv
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/265—Infectious rhinotracheitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/12011—Bunyaviridae
- C12N2760/12211—Phlebovirus, e.g. Rift Valley fever virus
- C12N2760/12234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Claims (8)
1. Эффективная жидкая стабильная комбинированная вакцина, способствующая защите крупного рогатого скота от клинического заболевания, которое возникает вследствие инфекции, вызванной вирусом вирусной диареи крупного рогатого скота (BVDV), и/или вирусом инфекционного бычьего ринотрахеита (IBR), и/или вирусом парагриппа типа 3 (PI3), и/или бычьим респираторно-синцитиальным вирусом (BRSV), и/или бычьим респираторным коронавирусом (BRCV), где указанная жидкая стабильная комбинированная вакцина содержит живой ослабленный BVDV, и/или живой ослабленный IBR, и/или живой ослабленный PI3, и/или живой ослабленный BRSV, и/или живой ослабленный BRCV вместе с 10-30% (масса/объем) сорбита, и количеством аминокислоты, выбранным из группы, состоящей из 0,17-0,46 моль аргинина или комбинированного общего 0,2-0,6 моль аргинина и глутаминовой кислоты; и, где жидкая стабильная комбинированная вакцина обладает рН от 6,0 до 8,0.
2. Жидкая стабильная комбинированная вакцина по п.1, в которой живой ослабленный BVDV выбран из группы, состоящей из BVDV1, BVDV2, и BVDV1 с BVDV2.
3. Жидкая стабильная комбинированная вакцина по п.1 или 2, дополнительно содержащая добавку сахара, которая является бесспиртовым сахаром, в которых комбинированное общее количество сахарного спирта и бесспиртового сахара в жидкой стабильной комбинированной вакцине составляет 20-40% (масса/объем).
4. Жидкая стабильная комбинированная вакцина по п.3, в которой бесспиртовой сахар выбран из группы, состоящей из сахарозы и трегалозы.
5. Жидкая стабильная комбинированная вакцина по п.1 или 2, которая дополнительно содержит бактерию.
6. Способ вакцинации крупного рогатого скота для помощи в защите от клинического заболевания, которое возникает вследствие инфекции, вызванной BVDV, и/или IBR, и/или PI3, и/или BRSV, и/или BRCV, включающий введение крупному рогатому скоту жидкой стабильной комбинированной вакцины по любому из пп.1-5.
7. Способ по п.6, в котором вышеупомянутое введение осуществляется путем подкожной инъекции, перорально или интраназально.
8. Способ производства жидкой комбинированной стабильной вакцины по п.1, включающий комбинирование терапевтически эффективного количества живого ослабленного BVDV, и/или живого ослабленного IBR, и/или живого ослабленного PI3, и/или живого ослабленного BRSV, и/или живого ослабленного BRCV вместе с 10-30% (масса/объем) сорбита и количества аминокислоты, выбранным из группы, состоящей из 0,17- 0,46 моль аргинина или комбинированного общего 0,2-0,6 моль аргинина и глутаминовой кислоты; и, где жидкая стабильная комбинированная вакцина обладает рН от 6,0 до 8,0.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361788982P | 2013-03-15 | 2013-03-15 | |
US61/788,982 | 2013-03-15 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015143465A Division RU2723935C2 (ru) | 2013-03-15 | 2014-03-14 | Жидкие стабильные вакцины, содержащие вирус крупного рогатого скота |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2021133045A Division RU2021133045A (ru) | 2013-03-15 | 2021-11-15 | Жидкие стабильные вакцины, содержащие вирус крупного рогатого скота |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2020117081A true RU2020117081A (ru) | 2020-07-16 |
RU2020117081A3 RU2020117081A3 (ru) | 2020-11-10 |
RU2759880C2 RU2759880C2 (ru) | 2021-11-18 |
Family
ID=50280384
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2020117081A RU2759880C2 (ru) | 2013-03-15 | 2014-03-14 | Жидкие стабильные вакцины, содержащие вирус крупного рогатого скота |
RU2015143465A RU2723935C2 (ru) | 2013-03-15 | 2014-03-14 | Жидкие стабильные вакцины, содержащие вирус крупного рогатого скота |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015143465A RU2723935C2 (ru) | 2013-03-15 | 2014-03-14 | Жидкие стабильные вакцины, содержащие вирус крупного рогатого скота |
Country Status (12)
Country | Link |
---|---|
US (2) | US9480739B2 (ru) |
EP (1) | EP2968511B1 (ru) |
JP (1) | JP6431489B2 (ru) |
AU (1) | AU2014230489B2 (ru) |
BR (1) | BR112015023507B1 (ru) |
CA (1) | CA2901232C (ru) |
ES (1) | ES2724575T3 (ru) |
HU (1) | HUE044302T2 (ru) |
MX (1) | MX359999B (ru) |
NZ (1) | NZ711697A (ru) |
RU (2) | RU2759880C2 (ru) |
WO (1) | WO2014140239A1 (ru) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
US9393298B2 (en) | 2013-03-15 | 2016-07-19 | Intervet Inc. | Liquid stable bovine virus vaccines |
US9480739B2 (en) | 2013-03-15 | 2016-11-01 | Intervet Inc. | Bovine virus vaccines that are liquid stable |
AR097762A1 (es) | 2013-09-27 | 2016-04-13 | Intervet Int Bv | Formulaciones secas de vacunas que son estables a temperatura ambiente |
AR099470A1 (es) | 2014-02-17 | 2016-07-27 | Intervet Int Bv | Vacunas de virus de aves de corral líquidas |
TWI670085B (zh) | 2014-02-19 | 2019-09-01 | 荷蘭商英特威國際公司 | 液體穩定之豬病毒疫苗 |
MX2017002803A (es) | 2014-09-03 | 2017-06-09 | Intervet Int Bv | Coronavirus bovino atenuado y vacunas relacionadas. |
CA2967532A1 (en) | 2014-11-24 | 2016-06-02 | Intervet International B.V. | Inactivated equine influenza virus vaccines |
NL2018155B1 (en) | 2017-01-11 | 2018-07-25 | Intervet Int Bv | Oral vaccine against ruminant respiratory disease |
AR113996A1 (es) | 2017-12-22 | 2020-07-08 | Intervet Int Bv | Vacunas líquidas de virus envueltos vivos |
AR118519A1 (es) | 2019-03-29 | 2021-10-20 | Intervet Int Bv | Estabilización de la bacteria mollicutes viva en una composición líquida |
CA3136496A1 (en) * | 2019-04-09 | 2020-10-15 | The Board Of Trustees Of The University Of Illinois | Drug adsorbed highly porous activated carbon for enhanced drug delivery |
WO2021045870A1 (en) * | 2019-09-06 | 2021-03-11 | Iowa State University Research Foundation, Inc. | Mirtazapine as a pre-shipping inhibitor of bovine respiratory disease |
AR127944A1 (es) | 2021-12-23 | 2024-03-13 | Intervet Int Bv | Vacunas líquidas estabilizadas de virus vivos |
CN116355857B (zh) * | 2023-05-10 | 2023-09-12 | 北京华夏兴洋生物科技有限公司 | 悬浮培养的牛肾细胞及其制备方法与应用 |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3155589A (en) | 1958-04-14 | 1964-11-03 | Upjohn Co | Parenteral extravascular injectable vaccines for simultaneous immunization of canidae against rabies, canine distemper, and infectious canine hepatitis |
GB1575155A (en) | 1978-04-11 | 1980-09-17 | Merck & Co Inc | Vaccine stabilizer |
PT71926B (en) | 1979-10-29 | 1982-03-31 | Merck & Co Inc | Process for preparing a liquid vaccine comprising a stabilizer |
US4337242A (en) | 1980-02-05 | 1982-06-29 | Merck & Co., Inc. | Vaccine stabilizer containing L-glutamic acid and L-arginine |
JPS589688A (ja) | 1981-07-06 | 1983-01-20 | Toyobo Co Ltd | 安定な酵素組成物 |
JPS6153227A (ja) | 1984-08-23 | 1986-03-17 | Biseibutsu Kagaku Kenkyusho:Kk | 日本脳炎・豚パルボウイルス感染症混合生ワクチン |
US4867975A (en) | 1988-01-27 | 1989-09-19 | University Of Delaware | Live attenuated temperature-sensitive avian infectious bronchitis virus vaccines and preparation and use thereof |
CA2075521C (en) | 1992-05-05 | 1995-11-28 | Kuniaki Koyama | Stabilized live vaccine |
US5443959A (en) | 1992-09-09 | 1995-08-22 | Tokuyama Corporation | Method of assaying fibrinogen, dry reagent therefor, and process for the preparation thereof |
EP0650734B1 (en) | 1993-10-28 | 1999-03-10 | Division Of Microbiology, Kyoto Biken Laboratories, Inc. | Pentavalent live viral vaccine |
FR2719479B1 (fr) | 1994-05-04 | 1996-07-26 | Sanofi Elf | Formulation stable lyophilisée comprenant une protéine: kit de dosage. |
US5565318A (en) | 1994-09-02 | 1996-10-15 | Pharmacia Biotech, Inc. | Room temperature stable reagent semi-spheres |
US5593824A (en) | 1994-09-02 | 1997-01-14 | Pharmacia Biotech, Inc. | Biological reagent spheres |
FR2742756B1 (fr) | 1995-12-22 | 1998-04-03 | Pasteur Merieux Serums Vacc | Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation |
US6403098B1 (en) * | 1996-09-26 | 2002-06-11 | Merck & Co., Inc. | Rotavirus vaccine formulations |
US5932223A (en) | 1996-09-26 | 1999-08-03 | Merck & Co., Inc. | Rotavirus vaccine formulations |
WO1999015670A1 (en) | 1997-09-25 | 1999-04-01 | Biotechnology Research And Development Corporation | LKTA DELETION MUTANT OF $i(P. HAEMOLYTICA) |
CN1053590C (zh) | 1998-10-19 | 2000-06-21 | 卫生部长春生物制品研究所 | 冻干甲型肝炎减毒活疫苗及其保护剂 |
US20030114482A1 (en) | 1999-12-15 | 2003-06-19 | Maurizio Pacifici | Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies |
US20040038878A1 (en) | 2000-08-04 | 2004-02-26 | Masahiko Tanikawa | Injectable protein formulations |
US7923023B2 (en) * | 2002-02-25 | 2011-04-12 | Astech International LLC | Method and composition for delivery of medicants to animals |
JP4902103B2 (ja) | 2002-04-11 | 2012-03-21 | メディミューン・エルエルシー | 凍結乾燥フォームによる生物活性材料の保存 |
CA2496750C (en) * | 2002-08-26 | 2014-10-21 | Pfizer Products Inc. | Vaccine for respiratory and reproductive system infections in cattle |
US6931888B2 (en) | 2003-02-07 | 2005-08-23 | Ferro Corporation | Lyophilization method and apparatus for producing particles |
EP2481819A1 (en) | 2003-02-25 | 2012-08-01 | MedImmune Vaccines, Inc. | Cross flow filtration in the production of stabilized influenza vaccine compositions |
AU2004254619B2 (en) | 2003-07-02 | 2009-05-21 | Biotechnology Research And Development Corporation | Acapsular P. multocida hyaE deletion mutants |
WO2005052116A2 (en) | 2003-11-19 | 2005-06-09 | Merck & Co., Inc. | Preservative-containing virus formulations |
BRPI0508941A (pt) * | 2004-03-17 | 2007-08-14 | Pharmacia & Upjohn Co Llc | método de vacinação contra infecção de bvdv testicular |
GB0503337D0 (en) | 2005-02-17 | 2005-03-23 | Glaxosmithkline Biolog Sa | Compositions |
US7959929B2 (en) | 2005-04-21 | 2011-06-14 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
EP1896610A2 (en) | 2005-05-03 | 2008-03-12 | Handylab, Inc. | Lyophilized pellets |
SI1954308T1 (sl) | 2005-09-16 | 2011-12-30 | Merial Ltd | Stabilizatorji za liofilizirana cepiva |
CN101360821A (zh) * | 2005-11-21 | 2009-02-04 | 圣诺菲·帕斯图尔有限公司 | 重组病毒的稳定制剂 |
EP2004144A1 (en) | 2005-12-02 | 2008-12-24 | Stichting Katholieke Universiteit | Method for obtaining hollow particles |
NZ567668A (en) * | 2005-12-07 | 2011-07-29 | Pfizer Prod Inc | Marked bovine viral diarrhea virus vaccines |
KR101501780B1 (ko) | 2006-01-24 | 2015-03-16 | 넥스바이오, 인코퍼레이티드 | 고분자 미소 구체들의 조제를 위한 기술 |
BRPI0711608B8 (pt) * | 2006-05-12 | 2021-05-25 | Bharat Biotech Int Ltd | composição liofilizada, uso de antígeno viral, método de tratamento ou prevenção de vírus associado, método de adaptação de um vírus de uma linhagem celular adequada |
CN101679954A (zh) | 2007-04-06 | 2010-03-24 | 伊维拉根公司 | 用于活的减毒病毒的方法和组合物 |
BRPI0811161A2 (pt) | 2007-05-18 | 2014-10-07 | Medimmune Llc | Conservação de materiais bioativos por espuma liofilizada. |
NZ582019A (en) | 2007-06-14 | 2012-07-27 | Univ Oklahoma State | Vaccines containing canine parvovirus genetic variants |
TWI436789B (zh) | 2008-01-21 | 2014-05-11 | Intervet Int Bv | 含有藥學化合物的顆粒之冷凍乾燥方法及含有此顆粒的藥學包 |
EP2143440A1 (fr) | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
US7998488B2 (en) | 2008-11-14 | 2011-08-16 | Baxter International Inc. | Vaccine formulations and uses thereof |
US8980610B2 (en) | 2008-11-20 | 2015-03-17 | Biogen Idec Ma Inc. | Arginine inactivation of viruses |
JP2012519471A (ja) | 2009-01-30 | 2012-08-30 | ザ・ボード・オブ・リージェンツ・フォー・オクラホマ・ステート・ユニバーシティ | 北米のイヌにおいて広まっているイヌジステンパーウイルスに基づく免疫原性組成物、ワクチンおよび診断法 |
TWI468157B (zh) | 2009-04-29 | 2015-01-11 | Intervet Int Bv | 形成錠劑的方法,進行該方法的系統及包含該錠劑的包裝物 |
TWI471127B (zh) | 2009-04-29 | 2015-02-01 | Intervet Int Bv | 供人類使用之口服崩解錠劑的製備方法、所製得之口服崩解錠劑、以及含有該口服崩解錠劑的包裝物 |
RU2403061C1 (ru) * | 2009-06-29 | 2010-11-10 | Автономная некоммерческая организация "Научно-исследовательский институт диагностики и профилактики болезней человека и животных" (АНО "НИИ ДПБ") | Вакцина инактивированная комбинированная против инфекционного ринотрахеита, парагриппа-3, респираторно-синцитиальной болезни, вирусной диареи и пастереллеза крупного рогатого скота |
US8557253B2 (en) | 2009-10-07 | 2013-10-15 | Sanofi Pasteur Sa | Stabilizing excipient for inactivated whole virus vaccine |
JP5891175B2 (ja) | 2009-12-11 | 2016-03-22 | バインド セラピューティックス インコーポレイテッド | 治療用粒子の凍結乾燥に対する安定製剤 |
PT2658570T (pt) * | 2010-12-27 | 2019-02-08 | Elanco Us Inc | Composições e métodos vacinais contra o vírus da diarreia viral bovina tipo 1b |
PL2959916T3 (pl) | 2011-02-17 | 2019-05-31 | Boehringer Ingelheim Vetmedica Gmbh | Nowy europejski szczep prrsv |
US20140017318A1 (en) | 2012-07-10 | 2014-01-16 | Kevin O'Connell | Method to produce a medicinal product comprising a biologically active protein and the resulting product |
US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
US9393298B2 (en) * | 2013-03-15 | 2016-07-19 | Intervet Inc. | Liquid stable bovine virus vaccines |
US9480739B2 (en) | 2013-03-15 | 2016-11-01 | Intervet Inc. | Bovine virus vaccines that are liquid stable |
AR097762A1 (es) | 2013-09-27 | 2016-04-13 | Intervet Int Bv | Formulaciones secas de vacunas que son estables a temperatura ambiente |
AR099470A1 (es) | 2014-02-17 | 2016-07-27 | Intervet Int Bv | Vacunas de virus de aves de corral líquidas |
TWI670085B (zh) | 2014-02-19 | 2019-09-01 | 荷蘭商英特威國際公司 | 液體穩定之豬病毒疫苗 |
-
2014
- 2014-03-10 US US14/202,454 patent/US9480739B2/en active Active
- 2014-03-14 MX MX2015012737A patent/MX359999B/es active IP Right Grant
- 2014-03-14 NZ NZ711697A patent/NZ711697A/en unknown
- 2014-03-14 ES ES14710257T patent/ES2724575T3/es active Active
- 2014-03-14 WO PCT/EP2014/055053 patent/WO2014140239A1/en active Application Filing
- 2014-03-14 HU HUE14710257 patent/HUE044302T2/hu unknown
- 2014-03-14 AU AU2014230489A patent/AU2014230489B2/en active Active
- 2014-03-14 US US14/775,003 patent/US9603924B2/en active Active
- 2014-03-14 EP EP14710257.8A patent/EP2968511B1/en active Active
- 2014-03-14 BR BR112015023507-7A patent/BR112015023507B1/pt active IP Right Grant
- 2014-03-14 RU RU2020117081A patent/RU2759880C2/ru active
- 2014-03-14 CA CA2901232A patent/CA2901232C/en active Active
- 2014-03-14 RU RU2015143465A patent/RU2723935C2/ru active
- 2014-03-14 JP JP2015562175A patent/JP6431489B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
RU2723935C2 (ru) | 2020-06-18 |
RU2015143465A (ru) | 2017-04-26 |
JP2016510794A (ja) | 2016-04-11 |
EP2968511A1 (en) | 2016-01-20 |
NZ711697A (en) | 2021-07-30 |
RU2020117081A3 (ru) | 2020-11-10 |
JP6431489B2 (ja) | 2018-11-28 |
WO2014140239A1 (en) | 2014-09-18 |
AU2014230489A1 (en) | 2015-09-10 |
CA2901232A1 (en) | 2014-09-18 |
MX359999B (es) | 2018-10-17 |
US20140271709A1 (en) | 2014-09-18 |
CA2901232C (en) | 2023-09-26 |
US9603924B2 (en) | 2017-03-28 |
ES2724575T3 (es) | 2019-09-12 |
RU2759880C2 (ru) | 2021-11-18 |
BR112015023507B1 (pt) | 2023-02-14 |
HUE044302T2 (hu) | 2019-10-28 |
EP2968511B1 (en) | 2019-02-27 |
MX2015012737A (es) | 2016-02-19 |
BR112015023507A2 (pt) | 2017-07-18 |
AU2014230489B2 (en) | 2018-06-28 |
US9480739B2 (en) | 2016-11-01 |
US20160030556A1 (en) | 2016-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2020117081A (ru) | Жидкие стабильные вакцины, содержащие вирус крупного рогатого скота | |
RU2020140649A (ru) | Сухие композиции вакцин, стабильные при комнатной температуре | |
HRP20191523T1 (hr) | Paraziticidne kombinacije spirocikličkog izoksazolina | |
HRP20200072T1 (hr) | Načini doziranja za spojeve klase ehinokandina | |
HRP20171512T1 (hr) | Derivati betulina | |
RU2015109724A (ru) | Жидкие стабильные вирусные вакцины | |
WO2014160463A8 (en) | Prefusion rsv f proteins and their use | |
RU2016137119A (ru) | Птичьи вирусные вакцины, которые являются стабильными в жидкой среде | |
IL276210B2 (en) | MERS-COV vaccine | |
JP2015527402A5 (ru) | ||
EA200500275A1 (ru) | Вакцина против инфекций респираторной и репродуктивной систем крупного рогатого скота | |
AP2002002568A0 (en) | Mycoplasma bovis vaccine and methods of reducing pneumonia in animals. | |
HRP20171864T1 (hr) | Nove stabilne soli pentadekapeptida, postupak za njihovu proizvodnju, njihova primjena u proizvodnji farmaceutskih pripravaka i njihova uporaba u liječenju | |
JP2014502619A5 (ru) | ||
JP2012528794A5 (ru) | ||
BR112012008338A2 (pt) | combinação de vacinas contra doenças do trato respiratório. | |
JP2016534062A5 (ru) | ||
MX2016007224A (es) | Vacuna contra el circovirus porcino tipo 2. | |
RU2021133045A (ru) | Жидкие стабильные вакцины, содержащие вирус крупного рогатого скота | |
HRP20171514T1 (hr) | Derivati indolouree supstituirani glukopiranozilom i njihova upotreba kao inhibitora sglt | |
FI3137094T3 (fi) | Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen | |
RU2008130944A (ru) | Гипериммунная поливалентная сыворотка против массовых вирусных болезней крупного рогатого скота (спви-крс) и способ ее применения | |
Makoschey et al. | Experimental safety and efficacy study for the concurrent use of an inactivated bluetongue serotype 8 vaccine with inactivated or live cattle vaccines. | |
WO2014140680A8 (en) | Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection | |
TH168425B (th) | องค์ประกอบสำหรับการป้องกันและการรักษาการติดเชื้อไมโคพลาสมา |